Noninvasive Characterization of Myocardial Diseases With Hypertrophic Phenotypes Using Integrated ECG/Echocardiographic Indices
Authors:
- Valentina AllegroVAValentina Allegro
- Linda PaguraLPLinda Pagura
- Aldostefano PorcariAPAldostefano Porcari
- Giulia BarbatiGBGiulia Barbati
- Simone LonghiSLSimone Longhi
- Beatrice MusumeciBMBeatrice Musumeci
- Alberto CiprianiACAlberto Cipriani
- Marco CanepaMCMarco Canepa
- Cristina ChimentiCCCristina Chimenti
- Rosa LilloRLRosa Lillo
- Francesca GrazianiFrancesca Graziani
- Giacomo BonacchiGBGiacomo Bonacchi
Open Access
- 6 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e043647
Abstract
Background: Indices reflecting the discordance between QRS complex voltages on ECG and left ventricular (LV) wall thickness or LV mass index on echocardiogram (echo) have enabled identification of cardiac amyloidosis (CA) among patients with hypertrophic hearts. However, this evidence comes from studies that have excluded patients with established hypertrophic cardiomyopathy (HCM) and Anderson‐Fabry disease (AFD). The aim of this study was to assess the performance of ECG/echo indices in characterizing adult patients with cardiomyopathies and hypertrophic phenotype. Methods: This was an Italian retrospective, cross‐sectional, multicenter study. Data from ECGs and echo of consecutive adult patients with confirmed CA, HCM, and AFD, and an LV wall thickness >12 mm were analyzed to calculate different ECG/echo indices. Results: Of the 1181 patients included (median age, 65 years; 69% men), 35.5% (n=416) had CA, 46.5% (n=594) had HCM, and 14.5% (n=171) had AFD. All ECG/echo indices were able to distinguish CA from other HCM and AFD ( P P <0.001 for all comparisons). Conclusions: ECG/echo indices, particularly total QRS/maximum LV wall thickness, may serve as easily accessible first‐line tools to differentiate CA from HCM and AFD. These findings may enable prompt recognition of patients with different cardiomyopathies in everyday clinical practice, both in community‐based centers and tertiary care facilities, and to orient subsequent diagnostic workup.Keywords
This publication has 27 references indexed in Scilit:
- Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL AmyloidosisJAMA Cardiology, 2024
- ECG/echo indexes in the diagnostic approach to amyloid cardiomyopathy: A head-to-head comparison from the AC-TIVE studyEuropean Journal of Internal Medicine, 2023
- Diagnosis and Management of Patients with Left Ventricular Hypertrophy: Role of Multimodality Cardiac Imaging. A Scientific Statement of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2023
- Low QRS Voltages in Cardiac AmyloidosisJACC: Cardiooncology, 2022
- Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide surveyEuropean Journal of Heart Failure, 2022
- Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathyInternational Journal of Cardiology, 2020
- The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathyHeart Rhythm, 2020
- Comparison of Functional Status, Electrocardiographic, and Echocardiographic Parameters to Mortality in Endomyocardial-Biopsy Proven Cardiac AmyloidosisThe American Journal of Cardiology, 2009
- Noninvasive diagnosis of biopsy-proven cardiac amyloidosisJACC, 2004
- Amyloid cardiomyopathy: Characterization by a distinctive voltage/mass relationThe American Journal of Cardiology, 1982